Tom Würdinger

8.6k citations

33 papers · 6.1k · 2 hit papers · h-index 17

Impact in

Cancer Research top 0.2%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Molecular Biology top 1%
- Extracellular vesicles in disease
- RNA Interference and Gene Delivery
- Circular RNAs in diseases

Papers in

Molecular Biology 18
- Extracellular vesicles in disease 8
- RNA Interference and Gene Delivery 3
- DNA Repair Mechanisms 2
Cancer Research 11
- MicroRNA in disease regulation 5
- Cancer Genomics and Diagnostics 4

Co-authors: Sjoerd van Rijn (1 shared paper)Johan Skog (1 shared paper)Dimphna H. Meijer (1 shared paper)Bob S. Carter (1 shared paper)William T. Curry (1 shared paper)Anna M. Krichevsky (1 shared paper)Xandra O. Breakefield (2 shared papers)Mark C. de Gooijer (3 shared papers)
Journals: Drug Resistance Updates (3 papers)Cancer Research (3 papers)Journal of Virology (2 papers)Clinical Cancer Research (2 papers)Gene Therapy (2 papers)
Partner nations: Netherlands United States Italy

In The Last Decade

Tom Würdinger

33 papers receiving 6.0k citations

Tom Würdinger's Hit Papers

align trajectories log scale

Overcoming the blood–brain tumor barrier for effective glioblastoma treatment 2015 · 817 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 Drug Resistance Updates
2008 Nature Cell Biology

Peers

Countries citing papers authored by Tom Würdinger

Since Specialization

Citations

This map shows the geographic impact of Tom Würdinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Würdinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Würdinger more than expected).

Fields of papers citing papers by Tom Würdinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Würdinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Würdinger. The network helps show where Tom Würdinger may publish in the future.

Co-authors

The 25 scholars most cited alongside Tom Würdinger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tom Würdinger Line = papers co-authored together Tom Würdinger links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers Nature Cell Biology ·Johan Skog, Tom Würdinger, Sjoerd van Rijn, Dimphna H. Meijer, Laura Gainche, William T. Curry, Bob S. Carter, Anna M. Krichevsky, Xandra O. Breakefield Hit paper breakdown →	2008	4185
2	Overcoming the blood–brain tumor barrier for effective glioblastoma treatment Drug Resistance Updates ·Olaf van Tellingen, Bahar Yetkin-Arik, Mark C. de Gooijer, Pieter Wesseling, Tom Würdinger, Helga E. de Vries Hit paper breakdown →	2015	817
3	WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe Clinical Cancer Research ·Philip C. De Witt Hamer, Shahryar E. Mir, David P. Noske, Cornelis J.F. Van Noorden, Tom Würdinger	2011	202
4	LMP1 association with CD63 in endosomes and secretion via exosomes limits constitutive NF‐κB activation The EMBO Journal ·Frederik J. Verweij, Monique A.J. van Eijndhoven, Erik Hopmans, Tineke Vendrig, Tom Würdinger, Ellen Cahir-McFarland, Elliott Kieff, Dirk Geerts, Rik van der Kant, Jacques Neefjes, Jaap M. Middeldorp, D. Michiel Pegtel	2011	200
5	Glycan modification of glioblastoma‐derived extracellular vesicles enhances receptor‐mediated targeting of dendritic cells Journal of Extracellular Vesicles ·Sophie A. Dusoswa, Sophie K. Horrevorts, Martino Ambrosini, Hakan Kalay, Nanne J. Paauw, Rienk Nieuwland, D. Michiel Pegtel, Tom Würdinger, Yvette van Kooyk, Juan J. García‐Vallejo	2019	103
6	PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models Clinical Cancer Research ·Fan Lin, Mark C. de Gooijer, Diana Hanekamp, G. Chandrasekaran, Levi C.M. Buil, Nishita Thota, Rolf W. Sparidans, Jos H. Beijnen, Tom Würdinger, Olaf van Tellingen	2016	68
7	Molecular therapy in the microRNA era The Pharmacogenomics Journal ·Tom Würdinger, Fabrício F. Costa	2006	66
8	Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors Gene Therapy ·Victor W. van Beusechem, D C J Mastenbroek, Petra B. van den Doel, Martine L.M. Lamfers, Jacques Grill, Tom Würdinger, Hidde J. Haisma, Herbert M. Pinedo, Winald R. Gerritsen	2003	63
9	Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness Cell Reports ·Nora Pencheva, Mark C. de Gooijer, Daniël J. Vis, Lodewyk F.A. Wessels, Tom Würdinger, Olaf van Tellingen, René Bernards	2017	52
10	Cooperative Involvement of the S1 and S2 Subunits of the Murine Coronavirus Spike Protein in Receptor Binding and Extended Host Range Journal of Virology ·Cornelis A. M. de Haan, Eddie te Lintelo, Zhen Li, Matthijs Raaben, Tom Würdinger, Berend‐Jan Bosch, Peter J. M. Rottier	2006	51
11	Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma EBioMedicine ·Rocco Sciarrillo, Anna Wojtuszkiewicz, Btissame El Hassouni, Niccola Funel, Paolo Gandellini, Tonny Lagerweij, Silvia Buonamici, Maxime Blijlevens, Eveline A. Zeeuw van der Laan, Nadia Zaffaroni, Marcello Deraco, Shigeki Kusamura, Tom Würdinger, Godefridus J. Peters, Carla F.M. Molthoff, Gerrit Jansen, Gertjan J.L. Kaspers, Jacqueline Cloos, Elisa Giovannetti	2018	50
12	RNA-Sequencing of Tumor-Educated Platelets, a Novel Biomarker for Blood-Based Sarcoma Diagnostics Cancers ·Kimberley M. Heinhuis, Sjors G. J. G. In ‘t Veld, Govert Dwarshuis, Daan van den Broek, Nik Sol, Myron G. Best, Frits van Coevorden, Rick L. Haas, Jos H. Beijnen, Winan J. van Houdt, Tom Würdinger, Neeltje Steeghs	2020	46
13	The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation Drug Resistance Updates ·Hamza Saleem, U. Kulsoom Abdul, Aslι Küçükosmanoğlu, Megan Houweling, Fleur M.G. Cornelissen, Dieter Henrik Heiland, Monika E. Hegi, Mathilde C.M. Kouwenhoven, David Bailey, Tom Würdinger, Bart A. Westerman	2019	39
14	Targeting non-human coronaviruses to human cancer cells using a bispecific single-chain antibody Gene Therapy ·Tom Würdinger, Monique H. Verheije, Matthijs Raaben, Berend‐Jan Bosch, Cornelis A. M. de Haan, Victor W. van Beusechem, Peter J. M. Rottier, Winald R. Gerritsen	2005	36
15	Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma Molecular Cancer Therapeutics ·Ravi S. Narayan, Ana Gasol, Paul L.G. Slangen, Fleur M.G. Cornelissen, Tonny Lagerweij, Hou Y.Y.E. Veldman, Rogier Dik, Jaap van den Berg, Ben J. Slotman, Tom Würdinger, Daphne A. Haas‐Kogan, Lukas J.A. Stalpers, Brigitta G. Baumert, Bart A. Westerman, Jan Theys, Peter Sminia	2017	20
16	A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer Oncotarget ·Tonny Lagerweij, Lotte Hiddingh, Dennis Biesmans, Matheus H. W. Crommentuijn, Jacqueline Cloos, Xiao‐Nan Li, Mari Kogiso, Bakhos A. Tannous, W. Peter Vandertop, David P. Noske, Gertjan J.L. Kaspers, Tom Würdinger, Esther Hulleman	2016	17
17	WINDOW consortium: A path towards increased therapy efficacy against glioblastoma Drug Resistance Updates ·Kulsoom Abdul, Megan Houweling, Fredrik Svensson, Ravi S. Narayan, Fleur M.G. Cornelissen, Aslι Küçükosmanoğlu, Emmanouil Metzakopian, Colin Watts, David Bailey, Tom Würdinger, Bart A. Westerman	2018	16
18	Redirecting Coronavirus to a Nonnative Receptor through a Virus-Encoded Targeting Adapter Journal of Virology ·Monique H. Verheije, Tom Würdinger, Victor W. van Beusechem, Cornelis A. M. de Haan, Winald R. Gerritsen, Peter J. M. Rottier	2006	15
19	Reducing severe fatigue in patients with diffuse glioma: a study protocol for an RCT on the effect of blended cognitive behavioural therapy Trials ·J G Röttgering, Linda Douw, Philip C. De Witt Hamer, Mathilde C.M. Kouwenhoven, Tom Würdinger, Peter M. van de Ven, Louise Sharpe, Hans Knoop, Martin Klein	2022	9
20	Rationale and Study Design of the IRENE-Trial (NVALT-16): A Phase II Trial to Evaluate Iressa Rechallenge in Advanced NSCLC Patients With an Activating EGFR Mutation Who Responded to an EGFR-TKI Used As First-Line or Previous Treatment Clinical Lung Cancer ·Justine L. Kuiper, Daniëlle A.M. Heideman, Tom Würdinger, Katrien Grünberg, Harry J.M. Groen, Egbert F. Smit	2014	9

About Tom Würdinger

Tom Würdinger is a scholar working on Molecular Biology, Cancer Research, Genetics, Oncology and Pulmonary and Respiratory Medicine, having authored 33 papers that have together received 6.1k indexed citations. Recurring topics across this work include Extracellular vesicles in disease (8 papers), Glioma Diagnosis and Treatment (8 papers), MicroRNA in disease regulation (5 papers), Cancer Genomics and Diagnostics (4 papers), Virus-based gene therapy research (4 papers), RNA Interference and Gene Delivery (3 papers), SARS-CoV-2 and COVID-19 Research (3 papers) and DNA Repair Mechanisms (2 papers). The work is most often cited by research in Cancer Research (2.9k citations), Molecular Biology (4.7k citations), Genetics (501 citations), Immunology and Allergy (170 citations) and Immunology (538 citations). Tom Würdinger has collaborated with scholars based in Netherlands, United States and Italy. Frequent co-authors include Sjoerd van Rijn, Johan Skog, Dimphna H. Meijer, Bob S. Carter, William T. Curry, Anna M. Krichevsky, Xandra O. Breakefield, Mark C. de Gooijer, Olaf van Tellingen and Pieter Wesseling. Their work appears in journals such as Drug Resistance Updates, Cancer Research, Journal of Virology, Clinical Cancer Research and Gene Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Tom Würdinger

Impact in

Papers in i

In The Last Decade

Tom Würdinger

Tom Würdinger's Hit Papers

Peers

Countries citing papers authored by Tom Würdinger

Fields of papers citing papers by Tom Würdinger

All Works

About Tom Würdinger

Explore authors with similar magnitude of impact

Papers in